GO:1990226 histone methyltransferase binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990226 (histone methyltransferase binding) is a molecular function defined as binding to a histone methyltransferase enzyme.
• This binding event recruits histone methyltransferases such as PRC2, EHMT2, NSD1, and Ash1 to chromatin, enabling site-specific histone methylation.
• Histone methyltransferase binding is essential for Polycomb-group silencing, enhancer regulation, and epigenetic reprogramming.
• Dysregulation of histone methyltransferase binding is linked to overgrowth syndromes, intellectual disability, and inflammatory diseases.
• Key experimental approaches include knockout, point mutation, knock-in, and overexpression models, combined with chromatin immunoprecipitation and methyltransferase activity assays.
• EDITGENE provides CRISPR-based services to dissect histone methyltransferase binding mechanisms in disease-relevant cell models.
Description
GO:1990226, histone methyltransferase binding, is a molecular function term in the Gene Ontology that describes the binding of a protein or complex to a histone methyltransferase enzyme. This interaction is fundamental to epigenetic regulation because it determines where and when histone methyltransferases deposit methyl marks on histone tails, thereby controlling gene expression programs. Histone methyltransferase binding is not merely a passive tethering event; it often involves allosteric regulation, substrate recognition, and feedback loops that fine-tune chromatin states. Researchers study this term to understand how chromatin-modifying complexes are recruited to specific genomic loci and how mutations in binding interfaces contribute to human disease. The importance of histone methyltransferase binding spans developmental biology, cancer epigenetics, and immunology, making it a central node in chromatin research.
histone methyltransferase binding At A Glance
| GO ID | GO:1990226 |
|---|---|
| GO term | histone methyltransferase binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to a histone methyltransferase enzyme, often to recruit or regulate its activity on chromatin |
| Related processes | Polycomb-group silencing, enhancer regulation, epigenetic reprogramming |
| Key examples | PRC2 subunits binding EZH2, Caf1 binding Ash1, NSD1 interactions |
| Disease relevance | Sotos syndrome, intellectual disability, inflammatory diseases |
What Is GO:1990226?
According to the Gene Ontology, GO:1990226 (histone methyltransferase binding) is defined as binding to a histone methyltransferase enzyme. This molecular function encompasses physical interactions between a protein and any enzyme that catalyzes the transfer of methyl groups to histone proteins. It does not include the catalytic activity of the methyltransferase itself, but rather the binding event that may recruit, stabilize, or regulate the enzyme. The term is used to annotate proteins that directly associate with histone methyltransferases such as EZH2, EHMT2, NSD1, or Ash1, often as part of larger chromatin-modifying complexes.
Why Is histone methyltransferase binding Important in Cell Biology?
Histone methyltransferase binding is critically important because it dictates the specificity and efficiency of histone methylation, a cornerstone of epigenetic gene regulation. Without proper binding interactions, histone methyltransferases cannot be targeted to the correct genomic regions, leading to aberrant gene expression that underlies developmental disorders and cancer. Moreover, this binding function is a point of vulnerability for therapeutic intervention, as disrupting protein-protein interactions between methyltransferases and their binding partners can modulate epigenetic states.
• Controls recruitment of Polycomb repressive complex 2 (PRC2) to target genes for H3K27 methylation.
• Regulates enhancer activity and cell fate decisions through NSD1 binding.
• Modulates inflammatory gene expression via EHMT2 interactions.
• Influences histone methylation patterns genome-wide, as revealed by high-resolution profiling.
• Mutations in genes encoding histone methyltransferase binding proteins cause overgrowth and intellectual disability.
• Provides a mechanism for feedback regulation of methyltransferase activity by unmodified histone tails.
• Serves as a target for epigenetic drugs aiming to disrupt oncogenic chromatin complexes.
• Enables experimental dissection of chromatin regulation using CRISPR knockouts and knock-ins.
Molecular Mechanism of histone methyltransferase binding
Recognition of histone methyltransferase enzymes
In simple terms: Binding proteins recognize and attach to histone methyltransferases.
The first step in histone methyltransferase binding involves specific protein-protein interaction domains that recognize the methyltransferase enzyme. For example, the PRC2 complex subunits bind to EZH2, the catalytic subunit responsible for H3K27 methylation. Similarly, Caf1 binds to Ash1 to regulate its methyltransferase activity. These interactions are often mediated by conserved domains such as WD40 repeats, SET domains, or zinc fingers, and they ensure that the methyltransferase is properly localized and regulated.
Allosteric regulation and substrate sensing
In simple terms: Binding can change the enzyme's shape or activity based on the histone state.
Histone methyltransferase binding is not static; it can allosterically regulate the enzyme's catalytic activity. Caf1 senses unmodified histone H3 and regulates Ash1 methyltransferase activity accordingly. This feedback mechanism ensures that methylation is deposited only when appropriate, preventing aberrant epigenetic marks. Similarly, PRC2 binding to nucleosomes stimulates its methyltransferase activity, linking binding to catalysis.
Recruitment to chromatin and complex assembly
In simple terms: Binding helps bring methyltransferases to the right places in the genome.
Binding proteins often serve as scaffolds that recruit histone methyltransferases to specific chromatin regions. NSD1 binds to enhancers and regulates transcriptional programs critical for cell fate. EHMT2 (G9a) interacts with various partners to modulate expression of target genes such as RRAGC. These recruitment events are essential for establishing and maintaining epigenetic landscapes, as demonstrated by high-resolution profiling of histone methylations.
Functional consequences for gene expression
In simple terms: The binding event ultimately controls whether genes are turned on or off.
The outcome of histone methyltransferase binding is often changes in gene expression. Polycomb-group silencing via PRC2 binding leads to H3K27me3 and transcriptional repression. In contrast, NSD1 binding at enhancers can promote active transcription. In monocytes, oxidized LDL induces epigenetic reprogramming that involves histone methyltransferase interactions, leading to proinflammatory cytokine production. Thus, the binding function is a key determinant of cellular phenotypes.
Key Genes Involved in GO:1990226 histone methyltransferase binding
The following genes encode proteins that either bind to histone methyltransferases or are themselves histone methyltransferases involved in binding interactions, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EZH2 | Catalytic subunit of PRC2; binds to other PRC2 subunits and nucleosomes | Polycomb silencing, cancer epigenetics |
| SUZ12 | PRC2 subunit that binds EZH2 and regulates its activity | H3K27 methylation, developmental disorders |
| EED | PRC2 subunit that binds histone tails and EZH2 | Allosteric activation of PRC2 |
| EHMT2 | Histone methyltransferase G9a; interacts with various binding partners | Inflammatory gene regulation, RRAGC expression |
| NSD1 | Histone methyltransferase that binds enhancers and other proteins | Sotos syndrome, enhancer regulation |
| Ash1 | Histone methyltransferase regulated by Caf1 binding | Feedback regulation by unmodified H3 |
| Caf1 | Binds Ash1 and senses histone H3 modification state | Regulation of methyltransferase activity |
| PRC2 | Polycomb repressive complex 2; binds nucleosomes and EZH2 | H3K27 methylation, gene silencing |
| H3 | Histone H3; substrate and binding partner in nucleosomes | Methylation target, chromatin structure |
| H4 | Histone H4; component of nucleosomes | Chromatin packaging, methylation crosstalk |
| RRAGC | Ras-related GTP binding C; expression regulated by EHMT2 | mTOR signaling, inflammation |
| NSD1 | Nuclear receptor binding SET domain protein 1 | Overgrowth syndromes |
| EZH2 | Enhancer of zeste homolog 2 | Cancer therapy target |
| EHMT2 | Euchromatic histone methyltransferase 2 | Epigenetic reprogramming |
| Ash1 | Absent, small, or homeotic discs 1 | Drosophila development |
| Caf1 | Chromatin assembly factor 1 | Histone chaperone and methyltransferase regulator |
| PRC2 | Polycomb repressive complex 2 | Stem cell maintenance |
How Is histone methyltransferase binding Regulated?
Histone methyltransferase binding is regulated at multiple levels. Allosteric regulation by histone tails, such as Caf1 sensing unmodified H3 to control Ash1 activity, provides a feedback mechanism. Post-translational modifications of binding partners can alter their affinity for methyltransferases. In inflammatory contexts, oxidized LDL induces long-term epigenetic reprogramming that involves changes in histone methyltransferase interactions. Additionally, the availability of cofactors and the composition of chromatin-modifying complexes influence binding dynamics.
histone methyltransferase binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NSD1 | Sotos syndrome, overgrowth with intellectual disability | Knockout or point mutation in cell lines, enhancer reporter assays |
| EZH2 | Cancer, Polycomb dysregulation | Knockout and overexpression in cancer cell lines, ChIP-seq |
| EHMT2 | Inflammatory diseases, metabolic regulation | Knockout in monocytes/macrophages, cytokine assays |
| Ash1 | Developmental disorders (Drosophila models) | Point mutations in Caf1 binding interface, activity assays |
| PRC2 subunits | Cancer, developmental syndromes | Knock-in of binding-deficient mutants, methyltransferase assays |
Sotos syndrome and overgrowth disorders
Mutations in NSD1, a histone methyltransferase that binds enhancers and other proteins, cause Sotos syndrome, characterized by overgrowth and intellectual disability. Disruption of NSD1 binding to chromatin leads to aberrant enhancer regulation and developmental defects. This highlights the critical role of histone methyltransferase binding in human development.
Cancer epigenetics
Altered histone methyltransferase binding can drive oncogenesis. For example, PRC2 binding and H3K27 methylation are frequently dysregulated in cancers. Targeting the binding interfaces between PRC2 subunits and EZH2 is a therapeutic strategy. High-resolution profiling of histone methylations has revealed widespread changes in cancer cells.
Inflammatory and metabolic diseases
Oxidized LDL induces epigenetic reprogramming in monocytes, involving histone methyltransferase binding events that lead to sustained proinflammatory cytokine production and foam cell formation. EHMT2 regulates RRAGC expression, linking histone methyltransferase binding to mTOR signaling and metabolic control.
From histone methyltransferase binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a binding protein affect histone methylation? | CRISPR knockout of the binding protein followed by Western blot for methyl marks |
| Does a specific point mutation disrupt binding to a methyltransferase? | Point mutation knock-in using CRISPR, co-immunoprecipitation |
| Can a tagged binding protein be used to map interactions? | Knock-in of an epitope tag, affinity purification mass spectrometry |
| Does overexpression of a binding protein alter gene expression? | Overexpression via lentiviral transduction, RNA-seq |
| Can a binding interface be targeted therapeutically? | Knock-in of binding-deficient mutant, drug sensitivity assays |
| Does a binding protein regulate enhancer activity? | Knockout in enhancer reporter cell lines, ChIP-seq |
How to Study the histone methyltransferase binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genomic binding sites of methyltransferases | Mapping H3K27me3 and PRC2 localization |
| Co-IP | Protein-protein interactions | Validating binding between EZH2 and SUZ12 |
| Methyltransferase assay | Enzymatic activity | Testing regulation by Caf1 |
| RNA-seq | Gene expression changes | Assessing effects of EHMT2 knockout |
| CRISPR screen | Genes required for a phenotype | Identifying regulators of epigenetic reprogramming |
| Western blot | Histone methylation levels | Quantifying H3K27me3 after knockout |
| Mass spectrometry | Protein interactions and modifications | Mapping binding partners of NSD1 |
| Reporter assays | Enhancer or promoter activity | Testing NSD1 binding at enhancers |
Chromatin immunoprecipitation (ChIP)
ChIP is used to map the genomic binding sites of histone methyltransferases and their binding partners. For example, ChIP-seq of EZH2 and H3K27me3 reveals Polycomb target genes. High-resolution profiling of histone methylations has been achieved using ChIP-seq.
Co-immunoprecipitation and pull-down assays
These methods detect physical interactions between binding proteins and histone methyltransferases. They are essential for validating binding interfaces and for testing the effects of point mutations.
Methyltransferase activity assays
In vitro methyltransferase assays measure the catalytic activity of enzymes like PRC2 or Ash1 in the presence or absence of binding partners. Such assays have shown that Caf1 regulates Ash1 activity and that PRC2 binding stimulates methylation.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes required for histone methyltransferase binding and function. These screens are powerful for discovering novel regulators of epigenetic processes.
How CRISPR Can Be Used to Study GO:1990226 histone methyltransferase binding
Knockout
CRISPR knockout of genes encoding histone methyltransferase binding proteins, such as EZH2 or EHMT2, allows researchers to assess loss-of-function phenotypes. For example, EHMT2 knockout alters RRAGC expression, and PRC2 subunit knockouts abolish H3K27 methylation.
Point Mutation
Point mutations can be introduced to disrupt specific binding interfaces without affecting other functions. This is useful for testing whether a particular interaction is required for methyltransferase activity, as shown for Caf1-Ash1 binding.
Knock-in
Knock-in of tagged or mutant versions of binding proteins enables affinity purification and imaging. For instance, knocking in an epitope tag on NSD1 facilitates ChIP and proteomics.
Overexpression
Overexpression of histone methyltransferase binding proteins can reveal gain-of-function effects on chromatin and gene expression. Overexpression of EHMT2 or NSD1 has been used to study enhancer regulation and inflammatory responses.
How EDITGENE Supports histone methyltransferase binding Research
Researchers studying histone methyltransferase binding-related genes often need to determine whether a candidate gene is causally involved in chromatin regulation, disease progression, or therapeutic response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for histone methyltransferase binding research.
Frequently Asked Questions About histone methyltransferase binding
What is GO:1990226?
GO:1990226 is the Gene Ontology term for histone methyltransferase binding, defined as binding to a histone methyltransferase enzyme.
What genes are involved in histone methyltransferase binding?
Key genes include EZH2, SUZ12, EED, EHMT2, NSD1, Ash1, and Caf1, which encode proteins that bind to or are histone methyltransferases.
How does histone methyltransferase binding regulate gene expression?
Binding recruits methyltransferases to specific chromatin regions, leading to histone methylation marks that either repress or activate transcription.
What diseases are associated with defects in histone methyltransferase binding?
Sotos syndrome, intellectual disability, cancer, and inflammatory diseases have been linked to mutations or dysregulation in these binding interactions.
What methods are used to study histone methyltransferase binding?
Common methods include ChIP-seq, co-immunoprecipitation, methyltransferase activity assays, and CRISPR-based screens.
Can CRISPR be used to study histone methyltransferase binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect binding mechanisms.
What is the role of PRC2 in histone methyltransferase binding?
PRC2 binds to EZH2 and nucleosomes to catalyze H3K27 methylation, a key repressive mark.
How does Caf1 regulate Ash1 methyltransferase?
Caf1 senses unmodified histone H3 and regulates Ash1 activity, providing a feedback mechanism.
What is the link between histone methyltransferase binding and inflammation?
Oxidized LDL induces epigenetic reprogramming involving histone methyltransferase interactions, leading to proinflammatory cytokine production.
How can EDITGENE help with histone methyltransferase binding research?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study these interactions.
Conclusion
Histone methyltransferase binding (GO:1990226) is a fundamental molecular function that governs the recruitment and regulation of histone methyltransferases, thereby shaping epigenetic landscapes and gene expression programs. Its dysregulation is implicated in developmental disorders, cancer, and inflammatory diseases, making it a prime target for research and therapeutic intervention. By leveraging CRISPR-based models and advanced bioinformatics, researchers can dissect the precise roles of binding interactions and identify new avenues for treatment.
References
- 1. Barski A et al.. 2007. High-resolution profiling of histone methylations in the human genome.. Cell 129(4):823-37 PMID: 17512414
- 2. Cao R et al.. 2002. Role of histone H3 lysine 27 methylation in Polycomb-group silencing.. Science 298(5595):1039-43 PMID: 12351676
- 3. Sun Z et al.. 2023. Chromatin regulation of transcriptional enhancers and cell fate by the Sotos syndrome gene NSD1.. Mol Cell 83(14):2398-2416.e12 PMID: 37402365
- 4. Hwang S et al.. 2020. Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein.. BMB Rep 53(11):576-581 PMID: 32684241
- 5. Bekkering S et al.. 2014. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes.. Arterioscler Thromb Vasc Biol 34(8):1731-8 PMID: 24903093
- 6. Nekrasov M et al.. 2005. Nucleosome binding and histone methyltransferase activity of Drosophila PRC2.. EMBO Rep 6(4):348-53 PMID: 15776017
- 7. Yoon E et al.. 2023. Caf1 regulates the histone methyltransferase activity of Ash1 by sensing unmodified histone H3.. Epigenetics Chromatin 16(1):15 PMID: 37118845
- 8. Tatton-Brown K et al.. 2017. Mutations in Epigenetic Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability.. Am J Hum Genet 100(5):725-736 PMID: 28475857
